2 Stocks Drawing Bearish Options Activity Today

Pacira BioSciences (PCRX) rose 44% to $36.30 after Viatris (VTRS) agreed to acquire it for $36.50 per share, valuing the deal at $1.65B. Despite the rally, options activity is bearish. Ring Energy (REI) also saw unusual options volume amid a price increase.

Original reporting
Published Oct 8, 2026, 3:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 3:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
2 Stocks Drawing Bearish Options Activity Today — source image
Decision brief

The 30-second read

$PCRXBullishHigh
01

Why it matters

The Pacira acquisition is a material event likely to move the stock, while Ring Energy's options flow signals market caution.

02

Market read

The buyout drives a sharp rally in PCRX, while bearish options on REI hint at potential downside, offering short‑term trading opportunities.

03

What to watch

Regulatory approval risk for the Viatris‑Pacira transaction could delay or derail the deal.

Relevance 9/10Novelty 9/10Timing: today

Background

The article highlights two stocks with notable options activity, focusing on a major acquisition and unusual bearish positioning.

Company-level read

Ticker impact

$PCRXBullishHigh confidence
Context

Viatris announced a $1.65B cash acquisition of Pacira at $36.50 per share, sending PCRX up 44% and triggering heavy bearish options volume.

Expected impact

likely short‑term downside pressure as traders hedge the rally

Evidence & confidence

The deal is a material M&A event; the stock has already surged, and the dominant bearish delta indicates traders expect a pull‑back.

$REIBearishMedium confidence
Context

Options traders posted unusually high bearish volume on Ring Energy despite the stock trading higher today.

Expected impact

potential near‑term price pressure

Evidence & confidence

No fundamental catalyst is cited; the bearish options signal market skepticism.

Market effects

The pharma M&A may spur further consolidation activity in the specialty drug space.

US biotech sector sees heightened volatility as the deal unfolds.

Large‑cap M&A adds to overall market breadth, influencing risk sentiment.

Counterpoint

Despite the buyout premium, the high price may already price in the deal, and bearish options suggest a pull‑back.

Key entities

  • Viatris Inc.

    Acquirer of Pacira BioSciences in a $1.65B cash deal.

  • Pacira BioSciences Inc.

    Target of the Viatris acquisition.

  • Ring Energy Inc.

    Energy producer with elevated bearish options volume.

Related articles

$PCRXLow

Pacira BioSciences, Inc. (PCRX): RDF has the right to terminate the agreement for an uncured material breach by the Company, in connection with its bankruptcy or insolvency or if it directly…

Pacira BioSciences, Inc. (PCRX) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. As previously disclosed, pursuant to an agreement entered into between the Research Development Foundation (“RDF”) and a wholly-owned subsidiary of Pacira BioSciences, Inc. (the “Company” or “Pacira”), the Company was required to pay RDF a low

$VTRSHighAI 8/10

VTRS Q3 2026 deep dive: new product launches and Pacira acquisition shape outlook

Viatris reported Q3 2026 revenue of $3.75 billion, missing estimates by 1.3%, but beat EPS and EBITDA expectations. The company raised full-year guidance for revenue, EPS, and EBITDA. Growth was driven by higher-margin products and new launches, while supply chain issues impacted some regions. The pending acquisition of Pacira BioSciences is expected to enhance EBITDA and expand product offerings.